Selected article for: "ade antibody disease enhancement and lung injury"
Author: CV Herst; S Burkholz; J Sidney; A Sette; PE Harris; S Massey; T Brasel; E Cunha-Neto; DS Rosa; WCH Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen
Title: An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design
  • Document date: 2020_2_27
    • ID: i55tm3hh_35
    Snippet: In addition, a peptide vaccine mitigates the risk of Antibody Disease Enhancement (ADE) seen in the context of a non-neutralizing antibody response to 360 a whole protein vaccine [75] [55] . Also, neutralizing antibodies directed against spike protein in SARS-CoV-1 patients have been associated with an increased risk of Acute Lung Injury (ALI) [35] . Specifically, patients succumbing to SARS-CoV-1 were found to develop a neutralizing antibody (NA.....
    Document: In addition, a peptide vaccine mitigates the risk of Antibody Disease Enhancement (ADE) seen in the context of a non-neutralizing antibody response to 360 a whole protein vaccine [75] [55] . Also, neutralizing antibodies directed against spike protein in SARS-CoV-1 patients have been associated with an increased risk of Acute Lung Injury (ALI) [35] . Specifically, patients succumbing to SARS-CoV-1 were found to develop a neutralizing antibody (NAb) response to spike protein faster than survivors after the onset of symptoms and the NAb titers 365 were higher in the patients who died compared with those who recovered [76] . To the extent to which antibody vaccines producing an antibody response against the spike protein in SARS-CoV-2 could increase the risk of ALI, this risk could also be mitigated by a using peptide vaccine as an alternative approach.

    Search related documents:
    Co phrase search for related documents
    • ALI risk increase and increase risk: 1
    • alternative approach and antibody response: 1, 2, 3, 4
    • alternative approach and increase risk: 1
    • alternative approach and NAb titer: 1
    • alternative approach and protein vaccine: 1
    • alternative approach and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8
    • antibody response and increase risk: 1, 2, 3, 4, 5, 6
    • antibody response and NAb response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • antibody response and NAb titer: 1, 2, 3, 4
    • antibody response and neutralize antibody: 1, 2, 3, 4, 5, 6, 7, 8
    • antibody response and peptide vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • antibody response and protein vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody response and SARS patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody response and SARS patient spike protein: 1, 2
    • antibody response and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody response and SARS spike protein antibody response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • antibody vaccine and SARS patient: 1, 2, 3, 4, 5, 6, 7
    • antibody vaccine and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody vaccine and SARS spike protein antibody response: 1, 2, 3